Monday November 10, 12:56 pm Eastern Time
Company Press Release
Oscar Gruss & Son Inc./Gargiulo Group Division Initiates Coverage with BUY on Vasomedical, Inc.
NEW YORK--(BUSINESS WIRE)--Nov. 10, 1997--Oscar Gruss & Son Incorporated/Gargiulo Group Division initiates research coverage of Vasomedical, Inc., Westbury, NY, with a BUY recommendation. NASDAQ: (VASO)
Alan Tuchman, M.D., equity analyst at the Gargiulo Group Division, believes the company's commercialization of EECP(R), a microprocessor-based medical device for the non-invasive, atraumatic treatment of patients with coronary artery disease may offer an alternative treatment to many heart disease patients. The company is currently focusing its efforts on one of its FDA-approved indications, the treatment of stable angina. Dr. Tuchman feels this new approach to angina and other cardiovascular problems makes EECP(R) an interesting, and potentially very remunerative, alternative to more invasive procedures.
A multicenter, double-blind study of the use of EECP(R) is to be presented November 11, 1997, at the American Heart Association annual scientific sessions in Orlando, Florida.
Dr. Tuchman gives details on Vasomedical, Inc., in a research report that can be obtained for a fee from the Gargiulo Group Division at (212) 952-1220.
Investment Rating: STRONG BUY: expected total annual return of greater than 25% over the next 12-18 months; BUY: expected total annual return in the range of 15-25% over the next 12-18 months; SPECULATIVE BUY: stock for investors who can afford risk; total annual return of 15% - 25% if anticipated contingencies materialize over the next 12 - 18 months, with the potential for high volatility; HOLD: stock is fairly valued and should provide returns which approximate returns expected from the broad market over the next 12-18 months; UNATTRACTIVE: stock is overvalued based on current and projected EPS., cash flow and dividend rate, and should underperform the broad market and the company's peer group over the next 12-18 months; SELL: stock is significantly overvalued based on current and projected EPS., cash flow and dividend rate, and should materially underperform the broad market and the company's peer group over the next 12-18 months. Other factors considered in the Investment Rating include the company's risk profile, including earnings predictability, financial position, industry position, technology risk, product risk, and other factors. The required annual return for a specific investment rating will be increased for stocks with greater financial, business, and/or earnings risk.
|
